Caliway Biopharmaceuticals Co. L
6919
Clasificación en acciones
#4346
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Precio por acción
$2.29
Capitalización bursátil
$3.56B
Cambio (1 día)
-2.50%
Cambio (1 año)
-57.22%
País
TW
Comercio Caliway Biopharmaceuticals Co. L (6919)
Categoría
Healthcare
Ganancias de Caliway Biopharmaceuticals Co. L (6919)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Caliway Biopharmaceuticals Co. L, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Caliway Biopharmaceuticals Co. L desde 2026 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
